Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by mercedesmanon Oct 29, 2022 10:19pm
262 Views
Post# 35058215

RE:So it is Baxter adding to their Spectral investment

RE:So it is Baxter adding to their Spectral investment

Thx & Congrats !

not an easy confirmation ( of Baxter's participation) to find in a smattering of legal documents filed with SeDAR on October 28th 

...and it was contained in one that is 60 pages long ! 

Classic Spectral Marketing. 


here's some clarity on another matter :

( note: I suspect Chief Marketing Officer should really read Chief Medical Officer) 

( appears that June 30th 2023 is a key date, and it suggests a ramp-up is expected by two key individuals. 8 months and counting.) 


 

PSUs Outstanding as at October 28, 2022
The Corporation granted to each of Chief Executive Officer and the Chief Marketing Officer of the Corporation a total of 3,000,000 PSUs (6,000,000 PSUs in total) which will vest immediately if FDA
        approval for the PMX Product is achieved by certain dates (the “PMX Milestone”) and shall be payable in Common Shares as follows to each Officer:
a. 2,250,000 Shares if the PMX Milestone is achieved before  June 30, 2023;
b. 1,875,000 Shares if the PMX Milestone is achieved on or after June 30, 2023 and before September 30, 2023;
c. 1,500,000 Shares if the PMX Milestone is achieved on or after September 30, 2023 and before December 31, 2023; and
d. 750,000 Shares if the PMX Milestone is achieved on or after December 31, 2023 and before January 31, 2024.
The PSUs will terminate and cease to have any effect with no payout in Common Shares if the PMX Milestone is not achieved by January 31, 2024.
The Corporation granted to each of Chief Executive Officer and the Chief Marketing Officer of the Corporation a total of 750,000 PSUs (1,500,000 PSUs in total) which will vest immediately if FDA approval for in-home use of DIMI is achieved by certain dates (the “DIMI Milestone”) and shall be payable in Common Shares as follows to each Officer:
LEGAL*57293396.2
B-1
 
 a. 750,000 Shares if the DIMI Milestone is achieved before June 30, 2024;
b. 500,000 Shares if the DIMI Milestone is achieved on or after June 30, 2024 and before September 30, 2024; and
c. 250,000 Shares if the DIMI Milestone is achieved on or after September 30, 2024 and before October 31, 2024.
The PSUs will terminate and cease to have any effect with no payout in Shares if the DIMI Milestone is not achieved by October 31, 2024.
<< Previous
Bullboard Posts
Next >>